Still, the most pronounced responses were observed either in patients with already approved organ-specific drug indications (e.g., olaparib in BRCA1/2-driven pancreatic cancer), or in subjects with overtly actionable lesions (ALK fusions, BRAF V600E mutations, microsatellite instability, etc.)[146]. This evidence concerns the gene BRAF and pancreatic neoplasm.